The U.S. Food and Drug Administration has approved a weight-loss pill from Novo Nordisk (NVO) that could speed up how appetite-suppressing drugs reach the mass market. The pill form of Wegovy, a GLP-1 drug that helps with weight loss, will be available starting in January. It offers the same effect as the injectable version but at a lower price and without the need for self-injection.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
This could expand access quickly. Many patients are more open to taking a daily pill than injecting themselves weekly. A cheaper pill also means insurers may be more willing to cover the treatment. Another drug company, Eli Lilly (LLY), is expected to gain approval for its own version next year.
Meanwhile, NVO shares climbed 1.84% on Wednesday, closing at $52.56.
Food Companies Begin to Adjust
As GLP-1 drugs go mainstream, changes in consumer behavior are already visible. According to a recent Cornell study, households using GLP-1 drugs cut grocery spending by 5.3% and fast-food spending by 8% on average. These trends often reverse when patients stop taking the drugs. However, the pill form could lead to longer-term use, which may bring more permanent shifts in food demand.
Analysts expect packaged food makers and restaurant chains to respond. Conagra Brands (CAG), Nestle (NESN), and others are already moving in that direction. Consumers of GLP-1s tend to choose smaller portions and prioritize protein and fiber. In response, companies are tweaking product labels, rolling out new recipes, and working with retailers to boost visibility.
Conagra said its Healthy Choice frozen meals labeled “GLP-1 friendly” are selling faster than competing meals with similar claims. More of these recipes will launch in May, supported by major retailers such as Walmart (WMT) and Kroger (KR).
Nestle has introduced a new frozen meal line, Vital Pursuit, targeting GLP-1 users. Danone (DANOY), which makes Oikos yogurt, reported double-digit growth in its high-protein offerings.
Fast-casual chains are adjusting, too. Chipotle (CMG) just launched a High Protein Menu that includes items such as a single-serve steak or chicken. Restaurants like Olive Garden have added smaller portion sizes. Noodles & Company said the goal is to offer meals that satisfy while staying light.
Longer-Term Consumer Shift Possible
Around 12% of U.S. adults say they currently take GLP-1 drugs. With pills entering the market, that number could grow. These medications are expected to be used longer because they are easier to take and less costly. Analysts say this could mean more lasting shifts in how people eat and shop.
As access to weight-loss pills improves, the ripple effects could reshape categories that rely on impulse purchases, large portions, or sugar-heavy products. While it is still early, the food sector is already adapting.
Is Novo Nordisk a Good Stock?
On the Street, Novo Nordisk boasts a Moderate Buy consensus, based on nine analysts’ ratings. The average NVO stock price target is $ 55.33, implying a 5.37% upside from the current price.
